Needham analyst Ami Fadia maintained a Buy rating on Neumora Therapeutics, Inc. today and set a price target of $6.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ami Fadia’s rating is based on several promising developments at Neumora Therapeutics, Inc. The company has recently unveiled a new program targeting obesity with NMRA-215, a high brain entrant NLRP3 inhibitor, which has shown potential in preclinical studies. This program is currently in a mouse study phase, with results expected in the fall, which could provide significant insights for human applications.
Additionally, the company’s pipeline continues to advance, with NMRA-511’s Phase 1b study in Alzheimer’s disease agitation expected to provide updates by the end of 2025. The management’s plan to host an R&D day in the fourth quarter to discuss the pipeline in detail further underscores their commitment to transparency and progress. These factors collectively contribute to the positive outlook and the Buy rating for Neumora Therapeutics, Inc.
According to TipRanks, Fadia is a 4-star analyst with an average return of 5.2% and a 46.21% success rate. Fadia covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Alkermes, and Jazz Pharmaceuticals.